Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ).
On March 16, 2026, Structure Therapeutics reported positive topline results from its Phase 2 ACCESS II trial of aleniglipron, showing statistically significant placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg over 44 weeks, with no evidence of a weight-loss plateau. Interim data from the ACCESS open-label extension showed continued weight loss up to 16.2% at 56 weeks with a 120 mg dose, while a separate body composition study and extension data indicated that a lower 2.5 mg starting dose and slower titration meaningfully improved tolerability and kept adverse event–related discontinuations in the low single digits.
Across more than 625 participants, aleniglipron has so far demonstrated a safety profile without drug-induced liver injury, persistent liver enzyme elevations or QTc prolongation, supporting its potential for chronic use in obesity treatment. These outcomes reinforce the drug’s positioning as a potentially best-in-class oral GLP-1 therapy and underpin Structure Therapeutics’ plan to move into Phase 3 trials, with an FDA End-of-Phase 2 meeting scheduled for the second quarter of 2026 and Phase 3 initiation targeted for the second half of 2026.
The most recent analyst rating on (GPCR) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.
Spark’s Take on GPCR Stock
According to Spark, TipRanks’ AI Analyst, GPCR is a Neutral.
The score is primarily driven by mixed financials: strong solvency and low leverage are outweighed by being pre-revenue with rising losses and a high cash burn rate. Technicals are weak (below key short-term averages with negative MACD), while recent corporate events are a notable positive catalyst (licensing cash infusion and supportive clinical results). Valuation provides limited support due to negative earnings and no dividend data.
To see Spark’s full report on GPCR stock, click here.
More about Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc. is a San Francisco-based, clinical-stage global biopharmaceutical company focused on developing novel oral small molecule therapeutics for metabolic diseases, particularly obesity and overweight conditions with related comorbidities. Its lead candidate, aleniglipron, is an investigational once-daily, nonpeptide GLP-1 receptor agonist intended to offer injectable-like efficacy in an oral form to broaden accessibility for patients.
Average Trading Volume: 1,010,152
Technical Sentiment Signal: Buy
Current Market Cap: $3.81B
For a thorough assessment of GPCR stock, go to TipRanks’ Stock Analysis page.